Skip to content

Arthritis Self-Management Education Program

Arthritis Self-Management Education -- Dose Response

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00467064
Enrollment
690
Registered
2007-04-27
Start date
2006-10-31
Completion date
2008-12-31
Last updated
2010-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthritis

Keywords

Disease self-management, Community programs

Brief summary

We will develop brief versions of the classic 6-week Arthritis Self-Management Program and evaluate their effectiveness.

Detailed description

Many national statements have been made recently about the importance of evidence-based arthritis self-management to improvements in the public's health. The prevalence of arthritis is increasing as the US population ages; the prevalence of arthritis-related disability is higher among Blacks than Whites. Effective arthritis self-management education programs with varying formats have been developed and found effective. Despite this, many Arthritis Foundation chapters and arthritis units of state health departments have found dissemination difficult, and cite the time demands (6 weekly sessions, 2 hours/session) of the classic arthritis self-management education program (ASMP) as a major barrier. Researchers at the University of North Carolina at Chapel Hill and Stanford University will develop and evaluate two low dose arthritis self-management programs. The study will be conducted in three phases. Phase One (Development): Researchers will conduct needs assessments with arthritis self-management program disseminators, rheumatologists and other arthritis health professionals, and potential program users to determine preferred content, length, and schedule. Using findings from these assessments, researchers will develop two low dose versions of the ASMP. Phase Two (Implementation and Evaluation): Researchers will evaluate the response (effectiveness) of both low dose interventions in a randomized controlled trial (4 months) and a longitudinal study (one year). We will measure four outcomes: (1) Self-Management Behaviors, (2) Arthritis Self-Efficacy, (3) Health-related Quality of Life (Self-reported Health, Pain, Disability, Fatigue, Activity Limitation, and Health Distress); and (4) Health Care Utilization. A sample of 700 adults with diagnosed arthritis or chronic joint pain, including 200 African Americans, will participate in the study. All data will be gathered via self-administered mailed questionnaires, with telephone follow-up as needed. We will use analysis of co-variance and structural equation modeling to evaluate effectiveness. Researchers will also compare the effectiveness of each new low dose program with the effectiveness of existing arthritis self-management education program options. Phase Three (Dissemination): We will consult with arthritis units of state health departments and state chapters of the Arthritis Foundation on program adoption and distribution.

Interventions

BEHAVIORALArthritis Quick Start

Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.

OTHERDelayed treatment intervention

After four months delay, participants in Control Group receive Experimental workshop.

Sponsors

Stanford University
CollaboratorOTHER
Centers for Disease Control and Prevention
CollaboratorFED
University of North Carolina, Chapel Hill
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adults, 18 years or older * Arthritis diagnosis * No prior participation in arthritis self-management

Design outcomes

Primary

MeasureTime frame
Self-Efficacy10-1-05-9-30-09

Secondary

MeasureTime frame
Self-reported health10-1-05-9-30-09

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026